Literature DB >> 34717924

Gastroparesis.

Michael Camilleri1, Kenton M Sanders2.   

Abstract

Gastroparesis is characterized by symptoms suggestive of, and objective evidence of, delayed gastric emptying in the absence of mechanical obstruction. This review addresses the normal emptying of solids and liquids from the stomach and details the myogenic and neuromuscular control mechanisms, including the specialized function of the pyloric sphincter, that result in normal emptying, based predominantly on animal research. A clear understanding of fundamental mechanisms is necessary to comprehend derangements leading to gastroparesis, and additional research on human gastric muscles is needed. The section on pathophysiology of gastroparesis considers neuromuscular diseases that affect nonsphincteric gastric muscle, disorders of the extrinsic neural control, and pyloric dysfunction that lead to gastroparesis. The potential cellular basis for gastroparesis is attributed to the effects of oxidative stress and inflammation, with increased pro-inflammatory and decreased resident macrophages, as observed in full-thickness biopsies from patients with gastroparesis. Predominant diagnostic tests involving measurements of gastric emptying, the use of a functional luminal imaging probe, and high-resolution antral duodenal manometry in characterizing the abnormal motor functions at the gastroduodenal junction are discussed. Management is based on supporting nutrition; dietary interventions, including the physical reduction in particle size of solid foods; pharmacological agents, including prokinetics and anti-emetics; and interventions such as gastric electrical stimulation and pyloromyotomy. These are discussed briefly, and comment is added on the potential for individualized treatments in the future, based on optimal gastric emptying measurement and objective documentation of the underlying pathophysiology causing the gastroparesis.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gastric Accommodation; Gastric Emptying; Gastroparesis

Mesh:

Year:  2021        PMID: 34717924      PMCID: PMC8678360          DOI: 10.1053/j.gastro.2021.10.028

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  180 in total

1.  Electrophysiological identification of vagally innervated enteric neurons in guinea pig stomach.

Authors:  M Schemann; D Grundy
Journal:  Am J Physiol       Date:  1992-11

Review 2.  Botulinum Toxin Injection for Treatment of Gastroparesis.

Authors:  Trisha S Pasricha; Pankaj J Pasricha
Journal:  Gastrointest Endosc Clin N Am       Date:  2018-09-28

3.  Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement.

Authors:  Michael L Hibbard; Christy M Dunst; Lee L Swanström
Journal:  J Gastrointest Surg       Date:  2011-07-01       Impact factor: 3.452

4.  A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial.

Authors:  Eva A Olausson; Stine Störsrud; Håkan Grundin; Mats Isaksson; Stig Attvall; Magnus Simrén
Journal:  Am J Gastroenterol       Date:  2014-01-14       Impact factor: 10.864

5.  Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis.

Authors:  Viktor J Horváth; Harsha Vittal; Andrea Lörincz; Hui Chen; Graça Almeida-Porada; Doug Redelman; Tamás Ordög
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

6.  Botulinum toxin A for the treatment of delayed gastric emptying.

Authors:  Frank K Friedenberg; Amiya Palit; Henry P Parkman; Alexandra Hanlon; Deborah B Nelson
Journal:  Am J Gastroenterol       Date:  2007-12-05       Impact factor: 10.864

7.  Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa.

Authors:  B P Herring; A M Hoggatt; A Gupta; S Griffith; A Nakeeb; J N Choi; M T Idrees; T Nowak; D L Morris; J M Wo
Journal:  Neurogastroenterol Motil       Date:  2017-10-20       Impact factor: 3.598

8.  Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit.

Authors:  Henry P Parkman; Emily P Sharkey; Linda A Nguyen; Katherine P Yates; Thomas L Abell; William L Hasler; William Snape; John Clarke; Ron Schey; Kenneth L Koch; Braden Kuo; Richard W McCallum; Irene Sarosiek; Madhusudan Grover; Gianrico Farrugia; James Tonascia; Pankaj J Pasricha
Journal:  Dig Dis Sci       Date:  2019-11-22       Impact factor: 3.199

9.  Interstitial cells of Cajal mediate enteric inhibitory neurotransmission in the lower esophageal and pyloric sphincters.

Authors:  S M Ward; G Morris; L Reese; X Y Wang; K M Sanders
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

10.  Transcriptomic signatures reveal immune dysregulation in human diabetic and idiopathic gastroparesis.

Authors:  Madhusudan Grover; Simon J Gibbons; Asha A Nair; Cheryl E Bernard; Adeel S Zubair; Seth T Eisenman; Laura A Wilson; Laura Miriel; Pankaj J Pasricha; Henry P Parkman; Irene Sarosiek; Richard W McCallum; Kenneth L Koch; Thomas L Abell; William J Snape; Braden Kuo; Robert J Shulman; Travis J McKenzie; Todd A Kellogg; Michael L Kendrick; James Tonascia; Frank A Hamilton; Gianrico Farrugia
Journal:  BMC Med Genomics       Date:  2018-08-07       Impact factor: 3.063

View more
  2 in total

Review 1.  Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.

Authors:  Rajan Singh; Hannah Zogg; Uday C Ghoshal; Seungil Ro
Journal:  Front Pharmacol       Date:  2022-01-25       Impact factor: 5.810

2.  Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial.

Authors:  Jan Martinek; Rastislav Hustak; Jan Mares; Zuzana Vackova; Julius Spicak; Eva Kieslichova; Marie Buncova; Daniel Pohl; Sunil Amin; Jan Tack
Journal:  Gut       Date:  2022-04-25       Impact factor: 31.793

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.